Page last updated: 2024-11-06

vindeburnol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

vindeburnol: eburnamine derivative; RN given refers to (3alpha,14beta)-(+) isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11346210
CHEMBL ID2107237
SCHEMBL ID12345800
MeSH IDM0130201

Synonyms (7)

Synonym
vindeburnol
ru 24722
68779-67-9
CHEMBL2107237
SCHEMBL12345800
1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18)-tetraen-17-ol
(15r,17r,19s)-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18)-tetraen-17-ol

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"The dose-response relationship of vindeburnol has been investigated by assessing postural activity in a population of elderly patients, using posturography, an objective method for measuring balance."( Dose-response relationship of vindeburnol based on spectral analysis of posturographic recordings.
Foulhoux, P; Le Go, A; Patat, A, 1985
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (25.00)18.7374
1990's12 (42.86)18.2507
2000's5 (17.86)29.6817
2010's4 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (6.45%)5.53%
Reviews1 (3.23%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (90.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]